Phase 1/2 Preliminary Data Readout for DM1 and FSHD Programs Read more about Phase 1/2 Preliminary Data Readout for DM1 and FSHD Programs 2026 MDA Clinical & Scientific Conference Read more about 2026 MDA Clinical & Scientific Conference TD Cowen 46th Annual Health Care Conference Read more about TD Cowen 46th Annual Health Care Conference Sarepta EMBARK Study 3 Year Topline Results Read more about Sarepta EMBARK Study 3 Year Topline Results 2026 JP Morgan Healthcare Conference Read more about 2026 JP Morgan Healthcare Conference 30th Annual International Congress of the World Muscle Society - 2025 Read more about 30th Annual International Congress of the World Muscle Society - 2025 Analyst Q&A Regarding LGMD Programs Read more about Analyst Q&A Regarding LGMD Programs Sarepta Update on Strategic Restructure and ELEVIDYS Label Read more about Sarepta Update on Strategic Restructure and ELEVIDYS Label Sarepta Safety Update for ELEVIDYS and Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne Read more about Sarepta Safety Update for ELEVIDYS and Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne 2025 ASGCT Annual Meeting Read more about 2025 ASGCT Annual Meeting Pagination Page 1 Next page ›› Subscribe to Conference Presentation Toolkit Print Page | Email Alerts | RSS Feeds | Contacts
Phase 1/2 Preliminary Data Readout for DM1 and FSHD Programs Read more about Phase 1/2 Preliminary Data Readout for DM1 and FSHD Programs
TD Cowen 46th Annual Health Care Conference Read more about TD Cowen 46th Annual Health Care Conference
Sarepta EMBARK Study 3 Year Topline Results Read more about Sarepta EMBARK Study 3 Year Topline Results
30th Annual International Congress of the World Muscle Society - 2025 Read more about 30th Annual International Congress of the World Muscle Society - 2025
Sarepta Update on Strategic Restructure and ELEVIDYS Label Read more about Sarepta Update on Strategic Restructure and ELEVIDYS Label
Sarepta Safety Update for ELEVIDYS and Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne Read more about Sarepta Safety Update for ELEVIDYS and Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
